Evaluate the impact of CardiolRx™ on myocardial recovery in acute myocarditis. A double-blind, placebo-controlled trial.
Cardiol has received IND authorization from the U.S FDA to conduct a Phase II multi-national trial designed to evaluate the efficacy and safety of CardiolRx™ in acute myocarditis – an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people less than 35 years of age. Learn more…
Evaluate the tolerance and safety of CardiolRx™ in patients with recurrent pericarditis. A Phase II Open-label Pilot Study.
Cardiol has received IND authorization from the U.S. FDA to conduct a Phase II open-label pilot study designed to evaluate the tolerance, safety and disease endpoints of CardiolRx™, in patients with recurrent pericarditis – the most common of pericardial diseases with symptoms that include debilitating chest pain, shortness of breath, and fatigue. Learn more…
Evaluate the efficacy and safety of CardiolRx™ in patients with COVID-19 and cardiovascular disease or risk factors. A double-blind , placebo-controlled trial.
CardiolRx™ is currently being evaluated in a Phase II/III multi-national study, the LANCER trial, to evaluate its safety and efficacy as a cardioprotective therapy to reduce major cardiorespiratory events and improve symptoms in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, CVD, and to investigate the impact of CardiolRx™ on key cardiac and inflammatory biomarkers. Learn more…
Cardiol is developing a subcutaneous cannabidiol formulation targeting the inflammation and fibrosis associated with the development and progression of heart failure – a chronic condition estimated to affect 64 million globally and a leading cause of death and hospitalization, with associated annual healthcare costs in the U.S. alone exceeding $30 billion. Learn more…
*The Company intends to seek Orphan Drug Designation for CardiolRx for acute myocarditis and recurrent pericarditis